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Moreover, a hyper-reactive VWF system characterized by
substantially elevated levels of VWF and a temporary
ADAMTS13 deﬁciency develops during liver transplanta-
tion [6]. Not only may this hyper-reactive primary hemo-
static system constitute a risk for development of intra- or
post-operative thrombosis (such as hepatic artery throm-
bosis), these ﬁndings also reinforce that a restrictive plate-
let transfusion policy is warranted, given the detrimental
Letters to the EditorTo the Editor:
In an elegant and comprehensive review of the literature, Violi
and coworkers conclude that primary hemostasis may not be
defective in patients with cirrhosis, and that a low platelet count
in these patients should not necessarily be considered as a bleed-
ing risk [1]. Whilst we concur with these conclusions, we wish to
make additional comments on platelet function in patients with
cirrhosis.effects of perioperative platelet transfusions. Importantly,
routine diagnostic tests of platelet function do not take
alterations in the VWF/ADAMTS13 balance into account.
Also during liver transplantation, the interpretation of
available platelet function tests should be performed with
care, and platelet tests other than a platelet countmay have
little value in guiding hemostatic management.
(3) Although platelet function in patients with cirrhosis is
presumably sufﬁcient to support hemostasis, and platelet
reactivity may in some cases be such that it even precipi-
tates thrombosis, little is known about the function of
cirrhotic platelets in processes other than cessation of
bleeding. It is well recognized that platelets have multiple
extra-hemostatic functions in processes including inﬂam-
mation, host defense, angiogenesis, tumor metastasis, and
wound healing. In liver biology, the extra-hemostatic func-
tions of plateletmay do both good and harm [7]. A variety of
molecules stored within platelet granules play a role in the
above mentioned processes. Furthermore, it may be that de
novo synthesis of proteins by platelets contributes to extra-
hemostatic functions of platelets [8]. The competence of
platelets to perform these extra-hemostatic functions in
patients with cirrhosis is incompletely known and requires
further study. It has been established that important plate-
let-derived molecules including 5-hydroxytryptamine
(serotonin) are deﬁcient in patientswith cirrhosis [9]. Given
the important role of serotonin in repair of damaged liver
tissue [10], platelets may be defective in repair as a result
of reduced serotonin content. It is not unthinkable that also
de novo platelet protein synthesis is compromised in plate-
lets from patients with cirrhosis.
In conclusion, although the available literature strongly sup-
ports that defects in primary hemostasis in patients with cirrho-
sis are more ﬁction than fact, many open questions remain.
Future studies should not only focus on the role of platelets in
bleeding and thrombosis, but also extra hemostatic functions of
platelets should be considered.
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The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.(1) Whereas routine diagnostic tests of platelet function such
as the skin bleeding time and suspension aggregometry
are frequently abnormal, in vivo platelet function may be
adequate as pointed out by Violi et al. Although intrinsic
platelet function under physiological ﬂow conditions has
been shown to be preserved, defective platelet–vessel wall
interactions due to anemia and thrombocytopenia are
present [2]. A dysbalanced von Willebrand factor (vWF)/
ADAMTS13 balance may (in part) compensate for these
indirect platelet defects. The net effect of all possible
changes in primary hemostasis in patients with cirrhosis
appears to be a systemwhich is in physiological hemostatic
balance [3]. Nevertheless, the balance in primary hemosta-
sis in these patients is presumably precarious, and patients
may experience either bleeding or thrombotic complica-
tions as a result of poorly understood mechanisms that
upset the balance in the primary hemostatic system. We
agree with Violi and coworkers that studies testing the pre-
dictive value of different platelet function tests for either
bleeding or thrombosis are required. However, until results
of such studies are available, we argue against routine use
of platelet function tests, including bleeding time and sus-
pension aggregometry, in the diagnostic work-up of
hemostasis of patients with cirrhosis, as it is at present
unclear how these test results should be interpreted. Even
the interpretation of the platelet count in a patient with cir-
rhosis is difﬁcult, as potential compensatory mechanisms
may be present. A recent study showed that ultrasound-
guided thoracentesis can be safely performed in patients
with platelet counts below 50,000/ll [4], although a plate-
let count below this level is considered a contraindication
for small invasive procedures such as thoracentesis, as
pointed out by Violi and coworkers. These ﬁndings rein-
force the need for prospective clinical studies on safety of
invasive procedures in patients with cirrhosis and amoder-
ate to severe thrombocytopenia.
(2) Platelet transfusions are frequently administered before or
during larger invasive procedures (including liver
transplantation) in patients with cirrhosis. We have
recently demonstrated that platelet function is preserved
throughout liver transplantation [5], although profound
hemostatic changes, including further changes in levels of
coagulation proteins and the potential occurrence of hyper-
ﬁbrinolysis, are known to occur during this procedure.Journal of Hepatology 2012 vol. 56 j 993–999
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Reply to: Platelet function in patients with cirrhosis
To the Editor:
We thank Drs. Lisman and Porte for their very interesting com-
ments concerning our review on the presence or absence of plate-
let dysfunction in liver cirrhosis. We agree that extrinsic and
intrinsic factors may contribute to maintain a normal primary
hemostasis in cirrhosis, despite potential defects due to thrombo-
cytopenia and anemia. Among the extrinsic factors, we agree that
the enhanced ratio vonWillebrand factor/ADAMTS 13 may have a
role. However, we have recently demonstrated the existence of a
novel intrinsic factor that could contribute to maintain a normal
hemostasis. We demonstrated that, upon stimulation, platelets
produce physiologic amounts of isoprostanes [1], which are
chemically stable eicosanoids derived from arachidonic acid
interaction with reactive oxidant species (ROS) [2]. In virtue of
these chemical characteristics, isoprostanes are useful in the late
phase of platelet activation, where they serve to propagate plate-
let aggregation via activation of the glycoprotein IIb/IIIa [1]. We
have recently discovered that the enzyme NADPH oxidase, one
of the most important cellular producers of ROS, has a key role
in the formation of platelet isoprostanes. Thus, in patients with
hereditary deﬁciency of the enzyme, platelet formation of iso-
prostanes is down-regulated. In particular, platelets from these
patients have impaired platelet activation, reinforcing the forma-
tion of isoprostanes as a relevant intracellular pathway for plate-
let function [1]. On the basis of these ﬁndings, we analyzed the
behavior of platelet isoprostanes and NADPH oxidase activation
in a population affected by cirrhosis. We found that platelet pro-
duction of isoprostanes was increased coincidentally with an up-
regulation of platelet NADPH oxidase, suggesting a cause-effect
relationship between them [3]. These changes were more evident
in patients with Child-Pugh’s classes B and C, indicating the
platelet over-expression of this pro-aggregating molecule typi-
cally occurs in patients with severe liver failure. This ﬁnding
was associated with systemic signs of platelet activation such
as enhanced soluble CD40L, corroborating the concept that in
liver cirrhosis platelets are more prone to be activated.
The fact that platelets possess all the armamentarium to acti-
vate NADPH oxidase [4,5] is of relevance, not only for the hemo-
static system, but also for the extra-hemostatic effects potentially
played by platelets. The important issue raised by Drs. Lisman
and Porte is still to be adequately addressed, even if there is evi-
dence of a role of platelets in tumor metastasis, wound healing
and, overall, inﬂammation. Our data contribute to further expand
the knowledge on the pro-inﬂammatory role of platelets in as
much as NADPH oxidase is an enzyme of the innate immune sys-
tem with a crucial role for the bacterial killing via the production
of ROS [6]. In this regard, platelets may represent another
important component of the innate immune system, potentially
involved in the atherosclerotic process [7,8]. Thus, ROS
generation by NADPH oxidase is used by platelets to oxidize
LDL which are ultimately taken up by macrophages via scavenger
receptors [9]. Such an extra-hemostatic effect may implicate a
key role for platelets in the inﬂammatory process that initiates
atherosclerotic disease. The impact of this phenomenon in liver
cirrhosis remains, however, to be established.
How the complexity of these platelet functions relates to the
progression of liver cirrhosis, including bleeding and thrombosis,
is still a matter of debate and needs further investigation. For this
reason, we fully agree with Drs. Lisman and Porte that, currently,
the use of routine in vivo and ex vivo tests to explore global plate-
let function in cirrhosis is not useful for clinicians. However,
future research may identify new platelet biomarkers that will
help better understand the role of platelets in the bleeding
and thrombotic events that complicate the clinical course of
cirrhosis.
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